Emily M Jutkiewicz

List of Publications by Year in Descending Order

59 papers	1,430 citations	23 h-index	37 g-index
65 ext. papers	1,629 ext. citations	4.5 avg, IF	4.46 L-index

#	Paper	IF	Citations
59	Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders.. *Biomedicines*, **2022**, 10,	4.8	2
58	Novel Antimuscarinic Antidepressant-like Compounds with Reduced Effects on Cognition. *Journal of Pharmacology and Experimental Therapeutics*, **2021**, 377, 336-345	4.7	2
57	The Buprenorphine Analogue BU10119 Attenuates Drug-Primed and Stress-Induced Cocaine Reinstatement in Mice. *Journal of Pharmacology and Experimental Therapeutics*, **2021**, 378, 287-299	4.7	2
56	Pharmacological Properties of -Opioid Receptor-Mediated Behaviors: Agonist Efficacy and Receptor Reserve. *Journal of Pharmacology and Experimental Therapeutics*, **2020**, 374, 319-330	4.7	7
55	Aromatic-Amine Pendants Produce Highly Potent and Efficacious Mixed Efficacy Opioid Receptor (MOR)/Opioid Receptor (DOR) Peptidomimetics with Enhanced Metabolic Stability. *Journal of Medicinal Chemistry*, **2020**, 63, 1671-1683	8.3	5
54	Comparison of the muscarinic antagonist effects of scopolamine and L-687,306. *Behavioural Pharmacology*, **2020**, 31, 359-367	2.4	2
53	The protein kinase C selective inhibitor, enzastaurin, attenuates amphetamine-stimulated locomotor activity and self-administration behaviors in rats. *Psychopharmacology*, **2019**, 236, 3231-3242	4.7	1
52	Dual Pharmacophores Explored via Structure-Activity Relationship (SAR) Matrix: Insights into Potent, Bifunctional Opioid Ligand Design. *Journal of Medicinal Chemistry*, **2019**, 62, 4193-4203	8.3	5
51	Loss of RGS Control at G Reveals a Balance Between Nociceptin and Mu-opioid Receptor Systems. *FASEB Journal*, **2019**, 33, 669.12	0.9	
50	Delta Opioid Receptors and Modulation of Mood and Emotion. *Handbook of Experimental Pharmacology*, **2018**, 247, 179-197	3.2	8
49	Synthesis and Pharmacological Evaluation of Novel C-8 Substituted Tetrahydroquinolines as Balanced-Affinity Mu/Delta Opioid Ligands for the Treatment of Pain. *ACS Chemical Neuroscience*, **2018**, 9, 1840-1848	5.7	11
48	In vivo effects of bpioid receptor agonist/bpioid receptor antagonist peptidomimetics following acute and repeated administration. *British Journal of Pharmacology*, **2018**, 175, 2013-2027	8.6	25
47	Role of signalling molecules in behaviours mediated by the opioid receptor agonist SNC80. *British Journal of Pharmacology*, **2018**, 175, 891-901	8.6	24
46	Tolerance to high-internalizing opioid receptor agonist is critically mediated by arrestin 2. *British Journal of Pharmacology*, **2018**, 175, 3050-3059	8.6	23
45	Protein Kinase C Inhibitors Attenuate Amphetamine-Stimulated Behaviors Through Direct and Indirect Mechanisms in Different Brain Regions. *FASEB Journal*, **2018**, 32, 820.2	0.9	
44	Role of the guanine nucleotide binding protein, G In the development of morphine tolerance and dependence. *Psychopharmacology*, **2018**, 235, 71-82	4.7	2
43	Role of hippocampal 5-HT1A receptors in the antidepressant-like phenotype of mice expressing RGS-insensitive G2 protein. *Neuropharmacology*, **2018**, 141, 296-304	5.5	2

42	Direct and Systemic Administration of a CNS-Permeant Tamoxifen Analog Reduces Amphetamine-Induced Dopamine Release and Reinforcing Effects. *Neuropsychopharmacology*, **2017**, 42, 1940-1949	8.7	19
41	Design, synthesis, and biological activity of 5Sphenyl-1,2,5,6-tetrahydro-3,3Sbipyridine analogues as potential antagonists of nicotinic acetylcholine receptors. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 4350-4353	2.9	2
40	Multiple DSM-5 substance use disorders: A national study of US adults. *Human Psychopharmacology* , **2017**, 32, e2625	2.3	46
39	The role of regulator of G protein signaling 4 in delta-opioid receptor-mediated behaviors. *Psychopharmacology*, **2017**, 234, 29-39	4.7	16
38	The behavioral effects of a mixed efficacy antinociceptive peptide, VRP26, following chronic administration in mice. *Psychopharmacology*, **2016**, 233, 2479-87	4.7	9
37	Effects of N-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy Opioid Receptor (MOR)/Opioid Receptor (DOR) Ligands. *Journal of Medicinal Chemistry*, **2016**, 59, 4985-98	8.3	30
36	Single prolonged stress effects on sensitization to cocaine and cocaine self-administration in rats. *Behavioural Brain Research*, **2015**, 284, 218-24	3.4	18
35	Preoperative ultra-rapid opiate detoxification for the treatment of post-operative surgical pain. *Medical Hypotheses*, **2015**, 84, 529-31	3.8	5
34	Selectivity and anti-Parkinson's potential of thiadiazolidinone RGS4 inhibitors. *ACS Chemical Neuroscience*, **2015**, 6, 911-9	5.7	34
33	Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy opioid receptor/opioid receptor ligands. *ACS Chemical Neuroscience*, **2015**, 6, 1428-35	5.7	22
32	Pre-existing differences in motivation for food and sensitivity to cocaine-induced locomotion in obesity-prone rats. *Physiology and Behavior*, **2015**, 152, 151-60	3.5	33
31	Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy Opioid Receptor (MOR) Agonists/Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities. *Journal of Medicinal Chemistry*, **2015**, 58, 8952-69	8.3	31
30	The Effects of RGS4 on Delta Opioid Receptor-mediated Behaviors in Mice. *FASEB Journal*, **2015**, 29, 929.7	0.9	
29	The Protein Kinase C Inhibitor Tamoxifen Inhibits Neurochemical and Reinforcing Behavioral Effects of Amphetamine. *FASEB Journal*, **2015**, 29, 930.11	0.9	1
28	Development of a bioavailable opioid receptor (MOPr) agonist, opioid receptor (DOPr) antagonist peptide that evokes antinociception without development of acute tolerance. *Journal of Medicinal Chemistry*, **2014**, 57, 3148-53	8.3	39
27	Synergistic activity between the delta-opioid agonist SNC80 and amphetamine occurs via a glutamatergic NMDA-receptor dependent mechanism. *Neuropharmacology*, **2014**, 77, 19-27	5.5	9
26	Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy opioid receptor (MOR) agonist/opioid receptor (DOR) antagonist ligands. *Journal of Medicinal Chemistry*, **2013**, 56, 2139-49	8.3	41
25	Endogenous opioids as physiological antidepressants: complementary role of receptors and dopamine. *Neuropsychopharmacology*, **2012**, 37, 303-4	8.7	18

24	L-DOPA attenuates nicotine withdrawal-induced behaviors in rats. *Pharmacology Biochemistry and Behavior*, **2011**, 98, 552-8	3.9	10
23	Opioid receptor coupling to G(b) plays an important role in opioid antinociception. *Neuropsychopharmacology*, **2011**, 36, 2041-53	8.7	23
22	Patterns of nicotinic receptor antagonism: nicotine discrimination studies. *Journal of Pharmacology and Experimental Therapeutics*, **2011**, 339, 194-202	4.7	48
21	The role of G in mu-opioid signaling and antinociception. *FASEB Journal*, **2010**, 24, 583.5	0.9	
20	A bacterial cocaine esterase protects against cocaine-induced epileptogenic activity and lethality. *Annals of Emergency Medicine*, **2009**, 54, 409-20	2.1	23
19	The selective delta opioid agonist SNC80 enhances amphetamine-mediated efflux of dopamine from rat striatum. *Neuropharmacology*, **2008**, 55, 755-62	5.5	16
18	The delta-opioid receptor agonist SNC80 [(+)-4-[alpha(R)-alpha-[(2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl]-(3-methoxybenzyl)-N,N-diethylbenzamide] synergistically enhances the locomotor-activating effects of some psychomotor stimulants, but not direct dopamine agonists, in rats. *Journal of Pharmacology and Experimental Therapeutics*, **2008**,	4.7	11
17	Nicotine and amphetamine acutely cross-potentiate their behavioral and neurochemical responses in female Holtzman rats. *Psychopharmacology*, **2008**, 200, 93-103	4.7	22
16	Effects of agonists with mixed efficacy profiles at the mu and kappa opioid receptor on amphetamine-mediated dopamine release. *FASEB Journal*, **2008**, 22, 712.8	0.9	
15	RB101-mediated protection of endogenous opioids: potential therapeutic utility?. *CNS Neuroscience & Therapeutics*, **2007**, 13, 192-205		21
14	Behavioral and neurobiological effects of the enkephalinase inhibitor RB101 relative to its antidepressant effects. *European Journal of Pharmacology*, **2006**, 531, 151-9	5.3	34
13	Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats. *Brain Research*, **2006**, 1069, 172-81	3.7	68
12	Rapid and robust protection against cocaine-induced lethality in rats by the bacterial cocaine esterase. *Molecular Pharmacology*, **2006**, 70, 1885-91	4.3	48
11	The convulsive and electroencephalographic changes produced by nonpeptidic delta-opioid agonists in rats: comparison with pentylenetetrazol. *Journal of Pharmacology and Experimental Therapeutics*, **2006**, 317, 1337-48	4.7	67
10	The antidepressant -like effects of delta-opioid receptor agonists. *Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics*, **2006**, 6, 162-9		93
9	The selective delta opioid agonist SNC80 increases amphetamine-mediated release of dopamine. *FASEB Journal*, **2006**, 20, A676	0.9	
8	Amphetamine-sensitized rats demonstrate enhanced nicotine-stimulated locomotor activity and dopamine overflow. *FASEB Journal*, **2006**, 20, A677	0.9	
7	Separation of the convulsions and antidepressant-like effects produced by the delta-opioid agonist SNC80 in rats. *Psychopharmacology*, **2005**, 182, 588-96	4.7	65

6	The effects of CRF antagonists, antalarmin, CP154,526, LWH234, and R121919, in the forced swim test and on swim-induced increases in adrenocorticotropin in rats. *Psychopharmacology*, **2005**, 180, 215-23	4.7	69
5	Comparison of peptidic and nonpeptidic delta-opioid agonists on guanosine 5SO-(3-[35S]thio)triphosphate ([35S]GTPgammaS) binding in brain slices from Sprague-Dawley rats. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 312, 1314-20	4.7	15
4	Differential behavioral tolerance to the delta-opioid agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzami in Sprague-Dawley rats. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 315, 414-22	4.7	36
3	Delta-opioid agonists: differential efficacy and potency of SNC80, its 3-OH (SNC86) and 3-desoxy (SNC162) derivatives in Sprague-Dawley rats. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 309, 173-81	4.7	51
2	Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. *Neuropsychopharmacology*, **2002**, 26, 744-55	8.7	141
1	Convulsant activity of a non-peptidic delta-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats. *Psychopharmacology*, **2002**, 164, 42-8	4.7	75